ReviewCold Spring Harbor perspectives in medicine2012
Leucine-rich repeat kinase 2 for beginners: six key questions.
Review in Cold Spring Harbor perspectives in medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Low-frequency genetic variants in GAK enhance Golgi function and protect against Parkinson's disease.medRxiv : the preprint server for health sciences · 2025Article
- Blocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson's disease.JCI insight · 2024Article
- MicroRNAs regulating autophagy: opportunities in treating neurodegenerative diseases.Frontiers in neuroscience · 2024Review
- Role of Receptor Interacting Protein (RIP) kinases in cancer.Genes & diseases · 2022Review
- Review
- The Double-Faceted Role of Leucine-Rich Repeat Kinase 2 in the Immunopathogenesis of Parkinson's Disease.Frontiers in aging neuroscience · 2022Review
- Novel targeted therapies for Parkinson's disease.Molecular medicine (Cambridge, Mass.) · 2021Review
- Sequential screening nominates the Parkinson's disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis.Neurobiology of disease · 2020Article
- Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates.International journal of molecular sciences · 2020Review
- LRRK2 in Parkinson disease: challenges of clinical trials.Nature reviews. Neurology · 2020Review
- Role of the endolysosomal system in Parkinson's disease.Journal of neurochemistry · 2019Review
- Proteomic Responses Under Cold Stress Reveal Unique Cold Tolerance Mechanisms in the Pacific White Shrimp (Frontiers in physiology · 2018Article
- Mechanisms of Parkinson's disease-related proteins in mediating secondary brain damage after cerebral ischemia.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2017Review
- MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease.Frontiers in molecular neuroscience · 2017Review
- Protein Kinases and Parkinson's Disease.International journal of molecular sciences · 2016Review
- Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci.Acta neuropathologica · 2016Article
- M1 and M2 immune activation in Parkinson's Disease: Foe and ally?Neuroscience · 2015Review
- LRRK2 mutations and neurotoxicant susceptibility.Experimental biology and medicine (Maywood, N.J.) · 2015Review
- Article
- Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7.Nature communications · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
There has been intense interest in leucine-rich repeat kinase 2 (LRRK2) since 2004, when mutations in the LRRK2 gene were discovered to cause dominantly inherited Parkinson's disease (PD). This article will address six basic questions about LRRK2 biology as it relates to PD, with particular emphasis on its discovery, current concepts of its physiological and pathological functions, and the strategies being used to discover how LRRK2 dysfunction causes PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.